Assessing the Causal Effects of Human Serum Metabolites on 5 Major Psychiatric Disorders

Jian Yang,Bin Yan,Binbin Zhao,Yajuan Fan,Xiaoyan He,Lihong Yang,Qingyan Ma,Jie Zheng,Wei Wang,Ling Bai,Feng Zhu,Xiancang Ma
DOI: https://doi.org/10.1093/schbul/sbz138
2020-01-01
Schizophrenia Bulletin
Abstract:Psychiatric disorders are the leading cause of disability worldwide while the pathogenesis remains unclear. Genome-wide association studies (GWASs) have made great achievements in detecting disease-related genetic variants. However, functional information on the underlying biological processes is often lacking. Current reports propose the use of metabolic traits as functional intermediate phenotypes (the so-called genetically determined metabotypes or GDMs) to reveal the biological mechanisms of genetics in human diseases. Here we conducted a two-sample Mendelian randomization analysis that uses GDMs to assess the causal effects of 486 human serum metabolites on 5 major psychiatric disorders, which respectively were schizophrenia (SCZ), major depression (MDD), bipolar disorder (BIP), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD). Using genetic variants as proxies, our study has identified 137 metabolites linked to the risk of psychiatric disorders, including 2-methoxyacetaminophen sulfate, which affects SCZ (P = 1.7 x 10(-5)) and 1-docosahexaenoylglycerophosp hocholine, which affects ADHD (P = 5.6 x 10(-5)). Fourteen significant metabolic pathways involved in the 5 psychiatric disorders assessed were also detected, such as glycine, serine, and threonine metabolism for SCZ (P =.0238), Aminoacyl-tRNA biosynthesis for both MDD (P =.0144) and ADHD (P =.0029). Our study provided novel insights into integrating metabolomics with genomics in order to understand the mechanisms underlying the pathogenesis of human diseases.
What problem does this paper attempt to address?